Companies › Lexicon Pharmaceuticals
1 active drug program in 5 registered trials: 3 Phase 3, 1 Phase 2, 1 Phase 1; Cardiovascular, Metabolic and endocrine; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sotagliflozin Sodium/glucose cotransporter 1 inhibitor; Sodium/glucose cotransporter 2 inhibitor | SLC5A1, SLC5A2 | Phase 3 | Obstructive Cardiomyopathy, Hypertrophic; Diabetic Nephropathies; Cardiovascular Diseases; Type 1 Diabetes | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06481891 | Sotagliflozin | Phase 3 | Obstructive Cardiomyopathy, Hypertrophic | Cardiovascular | Jan 2027 |
| NCT06435156 | Sotagliflozin | Phase 2 | Type 1 Diabetes | Cardiovascular | Oct 2027 |
| NCT05696366 | Sotagliflozin | Phase 1 | Type 1 Diabetes | Metabolic and endocrine | Jan 2028 |
| NCT06217302 | Sotagliflozin | Phase 3 | Diabetic Nephropathies | Cardiovascular | Dec 2028 |
| NCT06082063 | Sotagliflozin | Phase 3 | Cardiovascular Diseases | Cardiovascular | Jul 2029 |
Cash and short-term investments of $183m on 2026-09-30; operating cash outflow about $43m a year; runway about 51 months at that burn, to Jan 2031; 4 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Colgate Palmolive Vogenx THPharm Boryung Pharmaceutical AstraZeneca Getz Pharma Boehringer Ingelheim Dong-A ST Hangzhou Zhongmei Huadong Pharmaceutical JW Pharmaceutical
Vogenx Crystalys Therapeutics vTv Therapeutics Madrigal Pharmaceuticals Inhibikase Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.